Australia markets closed

Keymed Biosciences Inc. (2162.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
33.650+1.350 (+4.18%)
At close: 04:08PM HKT
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in CNY. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
Total revenue
327,187
100,063
110,269
0
Cost of revenue
15,065
2,585
17,200
0
Gross profit
312,122
97,478
93,069
0
Operating expenses
Research development
593,123
507,374
358,156
127,400
Selling general and administrative
165,236
133,912
92,454
21,548
Total operating expenses
699,531
575,742
464,388
135,467
Operating income or loss
-387,409
-478,264
-371,319
-135,467
Interest expense
16,224
8,219
11,133
14,309
Income before tax
-257,976
-303,597
-3,892,632
-818,848
Income tax expense
0
0
0
0
Income from continuing operations
-257,976
-303,597
-3,892,632
-818,848
Net income
-266,602
-308,115
-3,887,309
-818,583
Net income available to common shareholders
-266,602
-308,115
-3,887,309
-818,583
Basic EPS
-1.02
-1.18
-24.17
-3.02
Diluted EPS
-1.02
-1.18
-24.17
-3.02
Basic average shares
260,925
261,127
160,849
270,996
Diluted average shares
260,925
261,127
160,849
270,996